Boothbay Fund Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.46M | Sell |
274,127
-1,050,094
| -79% | -$9.41M | 0.05% | 335 |
|
|
2025
Q1 | $9.93M | Sell |
1,324,221
-60,412
| -4% | -$453K | 0.26% | 55 |
|
|
2024
Q4 | $10.4M | Buy |
1,384,633
+190,574
| +16% | +$1.43M | 0.26% | 79 |
|
|
2024
Q3 | $9.07M | Sell |
1,194,059
-941,204
| -44% | -$7.15M | 0.21% | 88 |
|
|
2024
Q2 | $13.2M | Buy |
2,135,263
+1,672,929
| +362% | +$10.3M | 0.31% | 35 |
|
|
2024
Q1 | $2.35M | Buy |
+462,334
| New | +$2.35M | 0.05% | 371 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 1974 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 1891 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 1691 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 1658 |
|
|
2020
Q1 | – | Sell |
-30,000
| Closed | -$104K | – | 760 |
|
|
2019
Q4 | $104K | Buy |
+30,000
| New | +$104K | 0.01% | 651 |
|
|
2018
Q4 | – | Sell |
-73,065
| Closed | -$557K | – | 586 |
|
|
2018
Q3 | $557K | Buy |
73,065
+59,065
| +422% | +$450K | 0.06% | 240 |
|
|
2018
Q2 | $80K | Buy |
+14,000
| New | +$80K | 0.01% | 568 |
|